Value Reimagined: Unlocking ROI And Efficiency In Drug Development

Total R&D cost per approved new drug has been estimated at $1.3 billion to $2.8 billion, and clinical trials account for 70% of total R&D expenditures. Against that backdrop, the habit of contracting CDMO, CRO, and clinical supply services separately draws closer scrutiny. Handovers, data silos, and coordination gaps are often blamed for inefficiency and delay, but putting a number on their cost is harder than describing it.
A risk-adjusted valuation from the Tufts Center for the Study of Drug Development, currently under peer review, takes on that question for oncology programs. It models six integration scenarios, covers both monoclonal antibodies and small molecules, and tests the results through sensitivity analyses. The answer is not uniform across development stages.
Customer case studies from a biotech, a large biopharma sponsor, and a global vaccine trial add operational detail to the modeled results. Download the white paper to see how the numbers fall.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.